Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Delivery
Research agreement forged to study nasal delivery for diabetes and Alzheimer
December 6th, 2004
Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced that the company has entered into separate agreements with two undisclosed research partners to evaluate the development of proprietary formulations for the nasal delivery of compounds useful for the treatment of type 2 diabetes and Alzheimer disease. Financial terms are not disclosed. Nastech will utilize its proprietary Tight Junction technology to screen intranasal formulations of both compounds for toxicity, stability and the ability to facilitate drug transport across the nasal mucosa using its proprietary in vitro high throughput screening model to develop and optimize intranasal...
Source: Obesity & Diabetes Week (2004-12-06)
|
